<?xml version='1.0' encoding='utf-8'?>
<document id="32104494"><sentence text="Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats."><entity charOffset="0-12" id="DDI-PubMed.32104494.s1.e0" text="Piperacillin" /><entity charOffset="47-57" id="DDI-PubMed.32104494.s1.e1" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s1.e0" e2="DDI-PubMed.32104494.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s1.e0" e2="DDI-PubMed.32104494.s1.e1" /></sentence><sentence text="To assess the mechanism of the pharmacokinetic interaction between piperacillin and tazobactam, renal excretion and pharmacokinetic studies of piperacillin/tazobactam were investigated in normal and bacteremia rats"><entity charOffset="67-79" id="DDI-PubMed.32104494.s2.e0" text="piperacillin" /><entity charOffset="84-94" id="DDI-PubMed.32104494.s2.e1" text="tazobactam" /><entity charOffset="143-155" id="DDI-PubMed.32104494.s2.e2" text="piperacillin" /><entity charOffset="156-166" id="DDI-PubMed.32104494.s2.e3" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e0" e2="DDI-PubMed.32104494.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e0" e2="DDI-PubMed.32104494.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e0" e2="DDI-PubMed.32104494.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e0" e2="DDI-PubMed.32104494.s2.e3" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e1" e2="DDI-PubMed.32104494.s2.e1" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e1" e2="DDI-PubMed.32104494.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e1" e2="DDI-PubMed.32104494.s2.e3" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e2" e2="DDI-PubMed.32104494.s2.e2" /><pair ddi="false" e1="DDI-PubMed.32104494.s2.e2" e2="DDI-PubMed.32104494.s2.e3" /></sentence><sentence text=" A bacteremia model was established to investigate the pharmacokinetic properties of piperacillin and tazobactam under different conditions"><entity charOffset="85-97" id="DDI-PubMed.32104494.s3.e0" text="piperacillin" /><entity charOffset="102-112" id="DDI-PubMed.32104494.s3.e1" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s3.e0" e2="DDI-PubMed.32104494.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s3.e0" e2="DDI-PubMed.32104494.s3.e1" /></sentence><sentence text=" Renal slices were taken to examine the uptake of piperacillin and tazobactam"><entity charOffset="50-62" id="DDI-PubMed.32104494.s4.e0" text="piperacillin" /><entity charOffset="67-77" id="DDI-PubMed.32104494.s4.e1" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s4.e0" e2="DDI-PubMed.32104494.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s4.e0" e2="DDI-PubMed.32104494.s4.e1" /></sentence><sentence text=" Pharmacokinetic studies of β-lactamase in rats were performed to study the contribution of rOat1/3 to the inhibition of tazobactam on β-lactamase"><entity charOffset="121-131" id="DDI-PubMed.32104494.s5.e0" text="tazobactam" /></sentence><sentence text=" The AUC (from 2" /><sentence text="93 ± 0" /><sentence text="58 to 6" /><sentence text="52 ± 1" /><sentence text="44 mg·min/ml) and the plasma clearance (CLP ) (from 2" /><sentence text="41 ± 1" /><sentence text="20 to 0" /><sentence text="961 ± 0" /><sentence text="212 ml/min/kg) of tazobactam were both altered after the intravenous coadministration of piperacillin and tazobactam in the bacteremia rats"><entity charOffset="18-28" id="DDI-PubMed.32104494.s14.e0" text="tazobactam" /><entity charOffset="89-101" id="DDI-PubMed.32104494.s14.e1" text="piperacillin" /><entity charOffset="106-116" id="DDI-PubMed.32104494.s14.e2" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s14.e0" e2="DDI-PubMed.32104494.s14.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s14.e0" e2="DDI-PubMed.32104494.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32104494.s14.e0" e2="DDI-PubMed.32104494.s14.e2" /><pair ddi="false" e1="DDI-PubMed.32104494.s14.e1" e2="DDI-PubMed.32104494.s14.e1" /><pair ddi="false" e1="DDI-PubMed.32104494.s14.e1" e2="DDI-PubMed.32104494.s14.e2" /></sentence><sentence text=" The renal clearance (CLR ) of tazobactam decreased from 1"><entity charOffset="31-41" id="DDI-PubMed.32104494.s15.e0" text="tazobactam" /></sentence><sentence text="30 ± 0" /><sentence text="50 to 0" /><sentence text="361 ± 0" /><sentence text="043 ml/min/kg" /><sentence text=" In summary, there was a beneficial interaction between piperacillin and tazobactam mediated by rOat1 and rOat3"><entity charOffset="56-68" id="DDI-PubMed.32104494.s20.e0" text="piperacillin" /><entity charOffset="73-83" id="DDI-PubMed.32104494.s20.e1" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s20.e0" e2="DDI-PubMed.32104494.s20.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s20.e0" e2="DDI-PubMed.32104494.s20.e1" /></sentence><sentence text=" Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through the inhibition of rOat1 and rOat3 in rats"><entity charOffset="1-13" id="DDI-PubMed.32104494.s21.e0" text="Piperacillin" /><entity charOffset="48-58" id="DDI-PubMed.32104494.s21.e1" text="tazobactam" /><pair ddi="false" e1="DDI-PubMed.32104494.s21.e0" e2="DDI-PubMed.32104494.s21.e0" /><pair ddi="false" e1="DDI-PubMed.32104494.s21.e0" e2="DDI-PubMed.32104494.s21.e1" /></sentence><sentence text=" The contribution rate of rOat1/3 for the synergistic effect was 20% when the two drugs were coadministered" /><sentence text="" /></document>